Finnish Laboratory Tests Nomenclature updated in July 2022

25

Jul 2022

On July 1, 2022, the Laboratory Tests Nomenclature (Laboratoriotutkimusnimikkeistö) was updated in Finland. The validity period of seven coronavirus tests was extended until June 30, 2023. Some examples of these tests are listed below:

  • 7900 “Panbio COVID-19 Ag Rapid Test, Abbott Rapid Diagnostics”;
  • 7901 “Flowflex SARS-CoV-2 Antigen rapid test, ACON Laboratories, Inc”;
  • 7902 “mariPOC SARS-CoV-2, ArcDia International Ltd”;
  • 7905 “SARS-CoV-2 Antigen Rapid Test, Roche (SD BIOSENSOR)”.

Two new codes in the field of physiology were added:

  • 6603 “Esophageal precision manometry, impedance measurement”;
  • 6604 “Sleep impedance pneumography, long-term recording”.

The Laboratory Tests Nomenclature is maintained by the Association of Local and Regional Authorities. Nomenclature codes cover studies in clinical chemistry, clinical physiology, clinical microbiology, clinical neurophysiology, genetics, and pathology. Nomenclature codes are used for the unification of coding of laboratory procedures in Finland. The Laboratory Tests Nomenclature is also used to code the tests in private settings with coverage from the national public payor (KELA).

The full details in Finnish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

10

Aug 2022

In July 2022, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (transcatheter tricuspid valve annuloplasty for tricuspid regurgitation, and transcatheter tricuspid valve leaflet repair for tricuspid regurgitation), one new Diagnostic Guidance (PLGF-based testing to help diagnose suspected preterm pre-eclampsia), and four new Medtech Innovation Briefings (ProciseDx point-of-care platform for IBD, RespiraSense for continuously monitoring respiratory rate, Lenus COPD Support Service, and cyanoacrylate glue for hernia mesh fixation). Also, five clinical guidelines were updated.

Read more

08

Aug 2022

In July 2022, the Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) published on its website five Digi-HTAs in the fields of eHealth and in-vitro diagnostics.

Read more

05

Aug 2022

In July 2022, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) announced the extension of temporary reimbursement for gene expression profile (GEP) testing for early-stage breast cancer detection until December 31, 2022, and for molecular biology tests by next-generation sequencing (NGS) until June 30, 2023.

Read more

22

Jul 2022

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2022. The most significant changes concern introducing and updating multiple EBM codes for IVD tests and adjusting tariffs and content of radiotherapy services.

Read more

14

Jul 2022

In June 2022, NHS England and NHS Improvement (NHSEI) defined timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23. Applications can be submitted at any time throughout the year. Applications submitted before August 31, 2022, will be reviewed and considered for inclusion in the April 2023 update to the Test Directory

Read more